For example, studies have shown a survival benefit in diabetic patients with pancreatic cancer that have been treated with metformin compared with patients treated with insulin or sulfonylureas.[32,33] However, there is limitation on applying registry data to elucidate the association between medication history and the occurrence of pancreatic cancer. Here, INS is linked to pancreatic neoplasm.